| Literature DB >> 28822631 |
Guodong Liu1, Gary Wong2, Shuo Su3, Yuhai Bi4, Frank Plummer5, George F Gao4, Gary Kobinger6, Xiangguo Qiu7.
Abstract
Ebola virus disease (EVD) was first described over 40 years ago, but no treatment has been approved for humans. The 2013-2016 EVD outbreak in West Africa has expedited the clinical evaluation of several candidate therapeutics that act through different mechanisms, but with mixed results. Nevertheless, these studies are important because the accumulation of clinical data and valuable experience in conducting efficacy trials under emergency circumstances will lead to better implementation of similar studies in the future. Here, we summarize the results of EVD clinical trials, focus on the discussion of factors that may have potentially impeded the effectiveness of existing candidate therapeutics, and highlight considerations that may help meet the challenges ahead in the quest to develop clinically approved drugs.Entities:
Keywords: Ebola virus; convalescent plasma; monoclonal antibody; small molecule inhibitor; therapeutics
Mesh：
Substances：
Year: 2017 PMID： 28822631 PMCID： PMC5743218 DOI： 10.1016/j.molmed.2017.07.002
Source DB: PubMed Journal: Trends Mol Med ISSN： 1471-4914 Impact factor: 11.951